US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) ...

Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

This unpredictable autoimmune disease presents unique challenges for people with it. This unpredictable autoimmune disease ...

Autoimmune thyroid disorders are common in lupus patients, but do not worsen disease outcomes, a new study finds. APS ...

An autoantibody associated with systemic lupus erythematosus may help improve the performance of immune checkpoint inhibitor ...

a: vs healthy control, *p<0.017. jSLE, juvenile SLE; jSSc, juvenile systemic sclerosis; NF-κB, nuclear factor-kappa B. Additionally, serum PPAR-γ levels in patients with jSLE showed a downward trend ...

Below, Kiana Cornejo, 24, shares her story about being pregnant with lupus and the challenges she has faced both during and ...